Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis

Catherine C. Smith, Amy Paguirigan, Grace R. Jeschke, Kimberly C. Lin, Evan Massi, Theodore Tarver, Chen-Shan Chin, Saurabh Asthana, Adam Olshen, Kevin J. Travers, Susana Wang, Mark J. Levis, Alexander E. Perl, Jerald P. Radich, Neil P. Shah

Blood (2017) 130 (1): 48–58.

https://doi.org/10.1182/blood-2016-04-711820

Published: 2017

Includes: Supplemental data

Journal Articles

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Mayumi Sugita, MD, Grace R Jeschke, Martin P. Carroll, MD, Alexander E. Perl, MD

Blood (2014) 124 (21): 2371.

https://doi.org/10.1182/blood.V124.21.2371.2371

Published: 2014

Journal Articles

Lineage- and Developmental Stage-Specific Patterns Of Auf-1 Isoform Expression Contribute To The Regulation Of Erythroid-Specific mRNAs

Sebastiaan Van Zalen, PhD, Grace R Jeschke, Elizabeth Hexner, MD, J. Eric Russell, MD

Blood (2013) 122 (21): 10.

https://doi.org/10.1182/blood.V122.21.10.10

Published: 2013

Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 141.

https://doi.org/10.1182/blood.V120.21.141.141

Published: 2012

Journal Articles

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

Alexander E Perl, MD, Grace R Jeschke, Catherine C Smith, MD, James K. Mangan, MD, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 2453.

https://doi.org/10.1182/blood.V120.21.2453.2453

Published: 2012

Journal Articles

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Blood (2012) 120 (21): 143.

https://doi.org/10.1182/blood.V120.21.143.143

Published: 2012

Journal Articles

Auf-1 and YB-1 Independently Regulate β-Globin mRNA Stability Through Interaction with Poly(A) Binding Protein

Sebastiaan van Zalen, PhD, Alyssa A Lombardi, Grace R Jeschke, Elizabeth O Hexner, MD, J. Eric Russell, MD

Blood (2012) 120 (21): 1020.

https://doi.org/10.1182/blood.V120.21.1020.1020

Published: 2012

Journal Articles

AUF-1 and YB-1 are critical determinants of β-globin mRNA expression in erythroid cells

Sebastiaan van Zalen, Grace R. Jeschke, Elizabeth O. Hexner, J. Eric Russell

Blood (2012) 119 (4): 1045–1053.

https://doi.org/10.1182/blood-2011-10-387316

Published: 2012

Includes: Supplemental data

Journal Articles

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,

Alexander E Perl, MD, Grace R Jeschke, Catherine C. Smith, MD, James K. Mangan, MD, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2011) 118 (21): 3502.

https://doi.org/10.1182/blood.V118.21.3502.3502

Published: 2011

Journal Articles

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During Trials Combining Sirolimus and Intensive Chemotherapy: Target Inhibition Enhances Response

Margaret Kasner, MD, Selina M. Luger, MD, Grace R Jeschke, Rosemarie Mick, MS, Martin Carroll, MD, Alexander E Perl, MD

Blood (2011) 118 (21): 230.

https://doi.org/10.1182/blood.V118.21.230.230

Published: 2011

Journal Articles

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,

Alexander E Perl, MD, Grace R Jeschke, Takashi Sato, Shiro Akinaga, Niranjan S. Rao, PhD, Maria R. Baer, MD, Mark J. Levis, MD, PhD, Martin Carroll, MD

Blood (2011) 118 (21): 3508.

https://doi.org/10.1182/blood.V118.21.3508.3508

Published: 2011

Journal Articles

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Catherine C. Smith, MD, Alexander E Perl, MD, Elisabeth Lasater, PhD, Chao Zhang, PhD, Grace R Jeschke, Lauren E. Damon, Martin Carroll, MD, Neil P. Shah, MD, PhD

Blood (2011) 118 (21): 764.

https://doi.org/10.1182/blood.V118.21.764.764

Published: 2011

Journal Articles

Cytoplasmic Regulators of β-Globin mRNA Are Structurally Modified During Erythroid Terminal Differentiation

Sebastiaan van Zalen, PhD, Grace R Jeschke, Elizabeth Hexner, MD, J. Eric Russell, MD

Blood (2011) 118 (21): 1093.

https://doi.org/10.1182/blood.V118.21.1093.1093

Published: 2011

Journal Articles

A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies

Elizabeth Hexner, MD, Selina M. Luger, MD, James K. Mangan, MD, PhD, Noelle V. Frey, MD, Grace R Jeschke, Dale Frank, MD, Ran Reshef, MD, Alison W. Loren, MD, Steven C. Goldstein, MD, Misha Rosenbach, M.D., Christopher Nowaczyk, Mindy Schuster, M.D., Edward A. Stadtmauer, MD, Bruce L Levine, PhD, Carl H. June, MD, Stephen G. Emerson, MD, PhD, David L. Porter, MD

Blood (2011) 118 (21): 3032.

https://doi.org/10.1182/blood.V118.21.3032.3032

Published: 2011

Journal Articles

Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis

Anna Kalota, PhD, Grace R Jeschke, Martin Carroll, MD, Elizabeth Hexner

Blood (2011) 118 (21): 2825.

https://doi.org/10.1182/blood.V118.21.2825.2825

Published: 2011

NARROW

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Lineage- and Developmental Stage-Specific Patterns Of Auf-1 Isoform Expression Contribute To The Regulation Of Erythroid-Specific mRNAs

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Auf-1 and YB-1 Independently Regulate β-Globin mRNA Stability Through Interaction with Poly(A) Binding Protein

AUF-1 and YB-1 are critical determinants of β-globin mRNA expression in erythroid cells

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During Trials Combining Sirolimus and Intensive Chemotherapy: Target Inhibition Enhances Response

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Cytoplasmic Regulators of β-Globin mRNA Are Structurally Modified During Erythroid Terminal Differentiation

A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies

Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only